This week in charts: ESMO’s winners and losers
The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.